Vertex Pharmaceuticals
VRTX
395 hedge funds and large institutions have $15.8B invested in Vertex Pharmaceuticals in 2014 Q1 according to their latest regulatory filings, with 42 funds opening new positions, 152 increasing their positions, 143 reducing their positions, and 29 closing their positions.
45% more first-time investments, than exits
New positions opened: 42 | Existing positions closed: 29
2% more funds holding
Funds holding: 387 → 395 (+8)
6% more call options, than puts
Call options by funds: $388M | Put options by funds: $365M
6% more repeat investments, than reductions
Existing positions increased: 152 | Existing positions reduced: 143
0.39% more ownership
Funds ownership: 94.46% → 94.85% (+0.39%)
0% more funds holding in top 10
Funds holding in top 10: 4 → 4 (0)
4% less capital invested
Capital invested by funds: $16.6B → $15.8B (-$714M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$195M |
| 2 |
Capital World Investors
Los Angeles,
California
|
+$96.8M |
| 3 |
D.E. Shaw & Co
New York
|
+$93.1M |
| 4 |
Fidelity Investments
Boston,
Massachusetts
|
+$70.6M |
| 5 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
+$65.4M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Adage Capital Partners
Boston,
Massachusetts
|
-$170M |
| 2 |
JP Morgan Chase
New York
|
-$125M |
| 3 |
Jennison Associates
New York
|
-$69M |
| 4 |
GVI
Green Valley Investors
Wilmington,
Delaware
|
-$62.7M |
| 5 |
Goldman Sachs
New York
|
-$60.4M |
VRTX Hedge Fund Activity: Q1 2014 in Review
395 of the 3,475 institutional investors tracked by Wall St. Rank reported a position in Vertex Pharmaceuticals (VRTX) for Q1 2014, worth a combined $15.8B — down 4.3% from $16.6B a quarter earlier.
Buyers outnumbered sellers: 42 funds opened new VRTX positions and 29 closed out — a net gain of 13 holders — while 152 added to existing stakes and 143 trimmed.
The largest buyer was T. Rowe Price Associates, adding an estimated $195M. The largest seller was Adage Capital Partners, cutting an estimated $170M.
- 395 institutional investors held Vertex Pharmaceuticals (VRTX) as of Q1 2014, up from 387 in Q4 2013.
- Funds reported $15.8B of Vertex Pharmaceuticals stock for Q1 2014, down 4.3% quarter-over-quarter.
- 42 funds opened new Vertex Pharmaceuticals positions in Q1 2014 and 29 closed out, a net change of +13 holders.
- The largest Vertex Pharmaceuticals buyer in Q1 2014 was T. Rowe Price Associates, an estimated $195M added.
- The largest Vertex Pharmaceuticals seller in Q1 2014 was Adage Capital Partners, an estimated $170M sold.
Based on aggregated 13F filings for Q1 2014.